Active drug targeting to cancer cells significantly improve the anti-tumor activity of nano-drug
Publish place: 3rd INTERNATIONAL NASTARAN CANCER SYMPOSIUM
Publish Year: 1396
نوع سند: مقاله کنفرانسی
زبان: English
View: 422
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
NASTARANCANSER03_183
تاریخ نمایه سازی: 7 اسفند 1396
Abstract:
The main challenge confronting liposomal Doxorubicin (Doxil) as the first FDA approved nano-drug (1995) is enhancing its therapeutic efficacy compared to free Doxorubicin. Recent studies have proposed that the clinical efficiency of liposomes in anticancer agent delivery can be further improved via active targeting strategy as a result of increasing specific targeting and drug delivery to cancer cells. The active targeting effect could be established by decoration of Doxil surface with well-defined targeting agent like an antibody as the most extensively studied ligand. In the context of antibody- mediated targeted cancer therapy, we evaluated the anti-tumor activity and therapeutic efficacy of Doxil, and that of Doxil modified with a monoclonal antibody (mAb) against different markers, which are of the most well-known surface markers associated with Cancer Stem Cells (CSCs). In this study the Targeted-Doxil groups exhibited significantly higher doxorubicin concentration (than Doxil) inside the tumor cells and consequently superior tumor growth inhibition in BALB/c mice bearing C-26 murine carcinoma while their circulation time and distribution profile remained comparable. These findings indicate the potential of antibody targeting in therapeutic efficacy improvement and provide proof-of- principle for actively tumor-targeting concept.
Keywords:
Colon Cancer , Colorectal Cancer , Cancer Stem Cells , Stem Cells and Cancer , Solid Tumors , Targeted Cancer Therapy , Chemotherapy
Authors
Leila Arabi
Nanotechnology Research Center, School Of Pharmacy, Mashhad University Of Medical Sciences, Mashhad,Iran
Ali Badiee
Nanotechnology Research Center, School Of Pharmacy, Mashhad University Of Medical Sciences, Mashhad,Iran
Mahmoud Reza Jaafari
Nanotechnology Research Center, School Of Pharmacy, Mashhad University Of Medical Sciences, Mashhad, Iran